ArticleJNCI cancer spectrum2019
Access to Clinical Trials for Adolescents and Young Adults With Cancer: A Meta-Research Analysis.
Article in JNCI cancer spectrum, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Challenges and Potential Solutions to Advance Global Cancer Drug Development.Therapeutic innovation & regulatory science · 2026Review
- Health behaviors among young adult cancer survivors and the importance of task self-efficacy.Journal of cancer survivorship : research and practice · 2026Article
- Hospitalization for medical conditions in adolescent and young adult cancer survivors: a nationwide cohort study using the Netherlands Cancer Registry.Journal of cancer survivorship : research and practice · 2026Article
- Article
- Stage-specific characterization of "early-onset colorectal cancer": Localized and synchronous metastatic disease.International journal of cancer · 2025Article
- Article
- Insights From Diverse Perspectives on Social Media Messages to Inform Young Adults With Cancer About Clinical Trials: Focus Group Study.JMIR formative research · 2025Article
- Cancer advocacy, barriers and associated factors among adolescents and young adults with cancer in Africa.Ecancermedicalscience · 2025Article
- Sharing is caring: a network collaborative approach to identify and address barriers in accessing clinical trials in adolescents and young adults with leukemia and lymphoma.Hematology. American Society of Hematology. Education Program · 2024Review
- Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center.Cancer medicine · 2024Article
- Access to Care for Adolescents and Young Adults With Cancer in the United States: State of the Literature.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Review
- Clinical development of new drugs for adults and children with cancer, 2010-2020.Journal of the National Cancer Institute · 2023Article
- Article
- Survival in Young Adults With Cancer Is Associated With Medicaid Expansion Through the Affordable Care Act.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Pediatric oncology drug development and dosage optimization.Frontiers in oncology · 2023Review
- European Cancer Organisation's Inequalities Network: Putting Cancer Inequalities on the European Policy Map.JCO global oncology · 2022Article
- Next Step for Global Adolescent and Young Adult Oncology: A Core Patient-Centered Outcome Set.Journal of the National Cancer Institute · 2022Article
- Shared barriers and facilitators to enrollment of adolescents and young adults on cancer clinical trials.Scientific reports · 2022Article
- The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Adherence to cardiomyopathy screening guidelines among adolescent and young adult cancer survivors exposed to chest radiation and/or anthracyclines.Journal of cancer survivorship : research and practice · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 18-year-old age limit for inclusion in clinical trials constitutes a hurdle for adolescents and young adults (AYAs) with cancer. We analyzed the impact of this age barrier on the access of AYAs to cancer trials and novel therapies.
methodsClinicalTrials.gov was searched to identify all the trials including patients with 10 malignancies relevant for AYAs (January 2007 to July 2018). The trials were categorized as pediatric (patients <18 y), adult (≥18 y), and transitional (including adult and pediatric patients). Transitional trials with a lower limit between 12 and 18 years and an upper limit younger than 40 years were considered AYA-specific.
resultsOf 2764 identified trials, 2176 were included: 79% adult, 19% transitional, 2% pediatric. Five trials were AYA-specific. The proportion of academic trials was higher for transitional (69%; 288 of 421) than for adult trials (48%; 832 of 1718) (
conclusionsAYAs have limited access to cancer trials and innovative therapies, with no improvement over the last decade. The 18-years-old age limit continues to be a major hurdle. Our findings are consistent with the internationally supported idea that age inclusion criteria in oncological trials should be changed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.